English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

WHILE there is a vast literature on the effects of oestrogens and androgens on tumours, only a few reports have appeared in the last two or three years on clinical experience with progestins in human cancer. Kelley and Baker (1961). have treated 21 cases of uterine cancer using various preparations of progestational agents. Stoll (1961) treated 2 patients with oral progestational steroid (Enavid) and noted a regression of their recurrent endometrial carcinomata. No reports on cases of malignant ovarian tumours and very few on breast cancer treated with progesterone were found in the literature. Twelve cases of advanced mammary carcinoma were treated by Douglas, Loraine and Strong (1960) who studied the effects of 19-norethistosterone oenanthate, an early non-marketed German product. Only one patient in their series showed a favourable response. The indications for the use of a hormone which appears to exert its biological activity through an influence on connective tissue structures need hardly be stressed. The availability of a long acting progesterone preparation in the form of Primolut Depot (Delalutin in U.S.A.) prompted, in 1957, the start of a study of its growthrestraining effects in a small series of cases of advanced malignant tumours of breast, ovary and uterus. The findings and the discussion of the rationale of treatment are the subject of this preliminary note.

Progesterone in the Treatment of Advanced Malignant Tumours of Breast, Ovary and Uterus